
ProMIS Neurosciences Receives FDA Fast Track Designation for PMN310 Alzheimer’s Treatment
ProMIS Neurosciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead Alzheimer’s disease (AD) therapeutic candidate, PMN310. The designation aims to accelerate the development and review of PMN310, …